［1］ WASCHKE J.The desmosome and pemphigus［J］.Histochem Cell Biol,2008,130(1):21-54.
［2］ HE B,GUO L,HU Y,et al.Desmocollin-2 inhibits cell proliferation and promotes apoptosis in hepatocellular carcinoma via the ERK/c-MYC signaling pathway［J］.Aging(Albany NY),2022,14(21):8805-8817.
［3］ 李荣雪，王青釭.桥粒胶糖蛋白在肿瘤中的研究进展［J］.临床和实验医学杂志,2015(18):1572-1574.
LI RX, WANG QQ.Research progress of desmoglycans in tumors［J］.Journal of Clinical and Experimental Medicine,2015(18):1572-1574.
［4］ JURCIC V,KUKOVIC J,ZIDAR N.Expression of desmosomal proteins in acantholytic squamous cell carcinoma of the skin［J］.Histol Histopathol,2015,30(8):945-953.
［5］ POHL GM,GOZ M,GAERTNER A,et al.Cardiomyopathy related desmocollin-2 prodomain variants affect the intracellular cadherin transport and processing［J］.Front Cardiovasc Med,2023,10:1127261.
［6］ FLEMMING S,LUISSINT AC,KUSTERS D,et al.Desmocollin-2 promotes intestinal mucosal repair by controlling integrin-dependent cell adhesion and migration［J］.Mol Biol Cell,2020,31(6):407-418.
［7］ HUDA RN,GHAFOOR S.Desmosomal protein regulation and clinical implications in oral mucosal tissues［J］.J Pak Med Assoc,2020,70(8):1425-1431.
［8］ DUKER I,SCHALLER J,ROSE C,et al.Subcorneal pustular dermatosis-type IgA pemphigus with autoantibodies to desmocollins 1,2,and 3［J］.Arch Dermatol,2009,145(10):1159-1162.
［9］ OHZONO A,SOGAME R,LI X,et al.Clinical and immunological findings in 104 cases of paraneoplastic pemphigus［J］.Br J Dermatol,2015,173(6):1447-1452.
［10］ DUSEK RL,ATTARDI LD.Desmosomes:new perpetrators in tumour suppression［J］.Nat Rev Cancer,2011,11(5):317-323.
［11］ COUTO OF,DVORCHIK I,CARR BI.Causes of death in patients with unresectable hepatocellular carcinoma［J］.Dig Dis Sci,2007,52(11):3285-3289.
［12］ KIM DY.Changing etiology and epidemiology of hepatocellular carcinoma:Asia and worldwide［J］.J Liver Cancer,2024,24(1):62-70.
［13］ WU W,HE X,ANDAYANI D,et al.Pattern of distant extrahepatic metastases in primary liver cancer:a SEER based study［J］.J Cancer,2017,8(12):2312-2318.
［14］ JIANG F,WU P.Regulating DSC2 expression affects the proliferation and apoptosis of prostate cancer cells［J］.Cancer Manag Res,2020,12:11453-11462.
［15］ ZHAO Y,JIAN W,GAO W,et al.RNAi silencing of c-Myc inhibits cell migration,invasion,and proliferation in HepG2 human hepatocellular carcinoma cell line:c-Myc silencing in hepatocellular carcinoma cell［J］.Cancer Cell Int,2013,13(1):23.
［16］ LIN CP,LIU JD,CHOW JM,et al.Small-molecule c-Myc inhibitor,10058-F4,inhibits proliferation,downregulates human telomerase reverse transcriptase and enhances chemosensitivity in human hepatocellular carcinoma cells［J］.Anticancer Drugs,2007,18(2):161-170.
［17］ LUI VW,GRANDIS JR.EGFR-mediated cell cycle regulation［J］.Anticancer Res,2002,22(1A):1-11.
［18］ LIU W,INNOCENTI F,CHEN P,et al.Interethnic difference in the allelic distribution of human epidermal growth factor receptor intron 1 polymorphism［J］.Clin Cancer Res,2003,9(3):1009-1012.
［19］ FANG WK,LIAO LD,ZENG FM,et al.Desmocollin-2 affects the adhesive strength and cytoskeletal arrangement in esophageal squamous cell carcinoma cells［J］.Mol Med Rep,2014,10(5):2358-2364.
［20］ YANG M,LING X,XIAO J.miR-141 exacerbates lung ischemia-reperfusion injury by targeting EGFR/beta-catenin axis-mediated autophagy［J］.Aging(Albany NY),2022,14(16):6507-6519.
［21］ KOLEGRAFF K,NAVA P,HELMS MN,et al.Loss of desmocollin-2 confers a tumorigenic phenotype to colonic epithelial cells through activation of Akt/beta-catenin signaling［J］.Mol Biol Cell,2011,22(8):1121-1134.
［22］ DAWSEY SP,TONUI S,PARKER RK,et al.Esophageal cancer in young people:a case series of 109 cases and review of the literature［J］.PLoS One,2010,5(11):e14080.
［23］ MARIETTE C,BALON JM,PIESSEN G,et al.Pattern of recurrence following complete resection of esophageal carcinoma and factors predictive of recurrent disease［J］.Cancer,2003,97(7):1616-1623.
［24］ FANG WK,GU W,LI EM,et al.Reduced membranous and ectopic cytoplasmic expression of DSC2 in esophageal squamous cell carcinoma: an independent prognostic factor［J］.Hum Pathol,2010,41(10):1456-1465.
［25］ FANG WK,LIAO LD,LI LY,et al.Down-regulated desmocollin-2 promotes cell aggressiveness through redistributing adherens junctions and activating beta-catenin signalling in oesophageal squamous cell carcinoma［J］.J Pathol,2013,231(2):257-270.
［26］ ZHANG G,ZHOU X,XUE L,et al.Accumulation of cytoplasmic beta-catenin correlates with reduced expression of E-cadherin,but not with phosphorylated Akt in esophageal squamous cell carcinoma:immunohistochemical study［J］.Pathol Int,2005,55(6):310-317.
［27］ DE CASTRO J,GAMALLO C,PALACIOS J,et al.beta-catenin expression pattern in primary oesophageal squamous cell carcinoma.Relationship with clinicopathologic features and clinical outcome［J］.Virchows Arch,2000,437(6):599-604.
［28］ MEYER N,PENN LZ.Reflecting on 25 years with MYC［J］.Nat Rev Cancer,2008,8(12):976-990.
［29］ SUNG H,FERLAY J,SIEGEL RL,et al.Global cancer statistics 2020:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries［J］.CA Cancer J Clin,2021,71(3):209-249.
［30］ KHAN K,HARDY R,HAQ A,et al.Desmocollin switching in colorectal cancer［J］.Br J Cancer,2006,95(10):1367-1370.
［31］ LOWNDES M,RAKSHIT S,SHAFRAZ O,et al.Different roles of cadherins in the assembly and structural integrity of the desmosome complex［J］.J Cell Sci,2014,127(Pt 10):2339-2350.
［32］ WICKLINE ED,DU Y,STOLZ DB,et al.gamma-Catenin at adherens junctions: mechanism and biologic implications in hepatocellular cancer after beta-catenin knockdown［J］.Neoplasia,2013,15(4):421-434.
［33］ SUN C,WEN K,ZHANG B,et al.DSC2 suppresses the growth of gastric cancer through the inhibition of nuclear translocation of gamma-catenin and PTEN/PI3K/AKT signaling pathway［J］.Aging(Albany NY),2023,15(13):6380-6399.
［34］ ZHOU YJ,XIONG YX,WU XT,et al.Inactivation of PTEN is associated with increased angiogenesis and VEGF overexpression in gastric cancer［J］.World J Gastroenterol,2004,10(21):3225-3229.
［35］ XIN Z,YAMAGUCHI A,SAKAMOTO K.Aberrant expression and altered cellular localization of desmosomal and hemidesmosomal proteins are associated with aggressive clinicopathological features of oral squamous cell carcinoma［J］.Virchows Arch,2014,465(1):35-47.
［36］ NAGEL JM,LAHM H,OFNER A,et al.gamma-Catenin acts as a tumor suppressor through context-dependent mechanisms in colorectal cancer［J］.Int J Colorectal Dis,2017,32(9):1243-1251.
［37］ BRAY F,FERLAY J,SOERJOMATARAM I,et al.Global cancer statistics 2018:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries［J］.CA Cancer J Clin,2018,68(6):394-424.
［38］ ROSHANDEL G,GHASEMI-KEBRIA F,MALEKZADEH R.Colorectal cancer:Epidemiology,risk factors,and prevention［J］.Cancers (Basel),2024,16:8.
［39］ HUO M,ZHAO Y,LIU X,et al.EGFR targeting enhances the efficiency of chemotherapy through inhibiting IRE1alpha-XBP1s pathway in colorectal cancer cells［J］.J Cancer,2020,11(15):4464-4473.
［40］ UZUN S,ISIK A,KATIPOGLU K,et al.Characterization of the subcellular distribution of phospho-beta-catenin in colorectal cancer［J］.In Vivo,2023,37(4):1576-1583.
［41］ PIAWAH S,VENOOK AP.Targeted therapy for colorectal cancer metastases: A review of current methods of molecularly targeted therapy and the use of tumor biomarkers in the treatment of metastatic colorectal cancer［J］.Cancer,2019,125(23):4139-4147.
［42］ KAMEKURA R,KOLEGRAFF KN,NAVA P,et al.Loss of the desmosomal cadherin desmoglein-2 suppresses colon cancer cell proliferation through EGFR signaling［J］.Oncogene,2014,33(36):4531-4536.
［43］ SIEGEL RL,MILLER KD,JEMAL A.Cancer statistics,2020［J］.CA Cancer J Clin,2020,70(1):7-30.
［44］ FENG RM,ZONG YN,CAO SM,et al.Current cancer situation in China:good or bad news from the 2018 Global cancer statistics［J］.Cancer Commun(Lond),2019,39(1):22.
［45］ SHAH RB,GHOSH D,ELDER JT.Epidermal growth factor receptor (ErbB1) expression in prostate cancer progression: correlation with androgen independence［J］.Prostate,2006,66(13):1437-1444.
［46］ KOKKINOS MI,MURTHI P,WAFAI R,et al.Cadherins in the human placenta--epithelial-mesenchymal transition (EMT) and placental development［J］.Placenta,2010,31(9):747-755.
［47］ TORRE LA,SIEGEL RL,WARD EM,et al.Global cancer incidence and mortality rates and trends-an update［J］.Cancer Epidemiol Biomarkers Prev,2016,25(1):16-27.
［48］ KENNECKE H,YERUSHALMI R,WOODS R,et al.Metastatic behavior of breast cancer subtypes［J］.J Clin Oncol,2010,28(20):3271-3277.
［49］ LAAKMANN E,WITZEL I,FASCHING PA,et al.Development of central nervous system metastases as a first site of metastatic disease in breast cancer patients treated in the neoadjuvant trials GeparQuinto and GeparSixto［J］.Breast Cancer Res,2019,21(1):60.
［50］ WEI S,SIEGAL GP.Metastatic organotropism:An intrinsic property of breast cancer molecular subtypes［J］.Adv Anat Pathol,2017,24(2):78-81.
［51］ HAN JY,CHE N,MO J,et al.Desmoglein 2 and desmocollin 2 depletions promote malignancy through distinct mechanisms in triple-negative and luminal breast cancer［J］.BMC Cancer,2024,24(1):532.
［52］ HANAHAN D,WEINBERG RA.Hallmarks of cancer:the next generation［J］.Cell,2011,144(5):646-674.
［53］ LAMBERT AW,PATTABIRAMAN DR,WEINBERG RA.Emerging biological principles of metastasis［J］.Cell,2017,168(4):670-691.
［54］ NGUYEN DX,BOS PD,MASSAGUE J.Metastasis:from dissemination to organ-specific colonization［J］.Nat Rev Cancer,2009,9(4):274-284.
［55］ ACETO N,BARDIA A,MIYAMOTO DT,et al.Circulating tumor cell clusters are oligoclonal precursors of breast cancer metastasis［J］.Cell,2014,158(5):1110-1122.
［56］ CHEUNG KJ,PADMANABAN V,SILVESTRI V,et al.Polyclonal breast cancer metastases arise from collective dissemination of keratin 14-expressing tumor cell clusters［J］.Proc Natl Acad Sci USA,2016,113(7):E854-E863.
［57］ SAIAS L,GOMES A,CAZALES M,et al.Cell-cell adhesion and cytoskeleton tension oppose each other in regulating tumor cell aggregation［J］.Cancer Res,2015,75(12):2426-2433.
［58］ REIMER F,BRYAN S,LEGLER K,et al.The role of the desmosomal protein desmocollin 2 in tumour progression in triple negative breast cancer patients［J］.Cancer Cell Int,2023,23(1):47.